The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria
Diet-induced obesity is associated with proteinuria and glomerular disease in humans and rodents. We have shown that in mice fed a high-fat diet, increased renal expression of the transcriptional factor sterol-regulatory element binding protein-1 (SREBP-1) plays a critical role in renal lipid accumu...
Saved in:
Published in | American Journal of Physiology - Renal Physiology Vol. 297; no. 6; pp. F1587 - F1596 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Physiological Society
01.12.2009
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Diet-induced obesity is associated with proteinuria and glomerular disease in humans and rodents. We have shown that in mice fed a high-fat diet, increased renal expression of the transcriptional factor sterol-regulatory element binding protein-1 (SREBP-1) plays a critical role in renal lipid accumulation and increases the activity of proinflammatory cytokines and profibrotic growth factors. In the current study, we have determined a key role of the farnesoid X receptor (FXR) in modulating renal SREBP-1 activity, glomerular lesions, and proteinuria. We found that feeding a Western-style diet to DBA/2J mice results in proteinuria, podocyte loss, mesangial expansion, renal lipid accumulation, and increased expression of proinflammatory factors, oxidative stress, and profibrotic growth factors. Treatment of these mice with the highly selective and potent FXR-activating ligand 6-α-ethyl-chenodeoxycholic acid (INT-747) ameliorates triglyceride accumulation by modulating fatty acid synthesis and oxidation, improves proteinuria, prevents podocyte loss, mesangial expansion, accumulation of extracellular matrix proteins, and increased expression of profibrotic growth factors and fibrosis markers, and modulates inflammation and oxidative stress. Our results therefore indicate that FXR activation could represent an effective therapy for treatment of abnormal renal lipid metabolism with associated inflammation, oxidative stress, and kidney pathology in patients affected by obesity. |
---|---|
AbstractList | Diet-induced obesity is associated with proteinuria and glomerular disease in humans and rodents. We have shown that in mice fed a high-fat diet, increased renal expression of the transcriptional factor sterol-regulatory element binding protein-1 (SREBP-1) plays a critical role in renal lipid accumulation and increases the activity of proinflammatory cytokines and profibrotic growth factors. In the current study, we have determined a key role of the farnesoid X receptor (FXR) in modulating renal SREBP-1 activity, glomerular lesions, and proteinuria. We found that feeding a Western-style diet to DBA/2J mice results in proteinuria, podocyte loss, mesangial expansion, renal lipid accumulation, and increased expression of proinflammatory factors, oxidative stress, and profibrotic growth factors. Treatment of these mice with the highly selective and potent FXR-activating ligand 6-α-ethyl-chenodeoxycholic acid (INT-747) ameliorates triglyceride accumulation by modulating fatty acid synthesis and oxidation, improves proteinuria, prevents podocyte loss, mesangial expansion, accumulation of extracellular matrix proteins, and increased expression of profibrotic growth factors and fibrosis markers, and modulates inflammation and oxidative stress. Our results therefore indicate that FXR activation could represent an effective therapy for treatment of abnormal renal lipid metabolism with associated inflammation, oxidative stress, and kidney pathology in patients affected by obesity. [PUBLICATION ABSTRACT] Diet-induced obesity is associated with proteinuria and glomerular disease in humans and rodents. We have shown that in mice fed a high-fat diet, increased renal expression of the transcriptional factor sterol-regulatory element binding protein-1 (SREBP-1) plays a critical role in renal lipid accumulation and increases the activity of proinflammatory cytokines and profibrotic growth factors. In the current study, we have determined a key role of the farnesoid X receptor (FXR) in modulating renal SREBP-1 activity, glomerular lesions, and proteinuria. We found that feeding a Western-style diet to DBA/2J mice results in proteinuria, podocyte loss, mesangial expansion, renal lipid accumulation, and increased expression of proinflammatory factors, oxidative stress, and profibrotic growth factors. Treatment of these mice with the highly selective and potent FXR-activating ligand 6-alpha-ethyl-chenodeoxycholic acid (INT-747) ameliorates triglyceride accumulation by modulating fatty acid synthesis and oxidation, improves proteinuria, prevents podocyte loss, mesangial expansion, accumulation of extracellular matrix proteins, and increased expression of profibrotic growth factors and fibrosis markers, and modulates inflammation and oxidative stress. Our results therefore indicate that FXR activation could represent an effective therapy for treatment of abnormal renal lipid metabolism with associated inflammation, oxidative stress, and kidney pathology in patients affected by obesity.Diet-induced obesity is associated with proteinuria and glomerular disease in humans and rodents. We have shown that in mice fed a high-fat diet, increased renal expression of the transcriptional factor sterol-regulatory element binding protein-1 (SREBP-1) plays a critical role in renal lipid accumulation and increases the activity of proinflammatory cytokines and profibrotic growth factors. In the current study, we have determined a key role of the farnesoid X receptor (FXR) in modulating renal SREBP-1 activity, glomerular lesions, and proteinuria. We found that feeding a Western-style diet to DBA/2J mice results in proteinuria, podocyte loss, mesangial expansion, renal lipid accumulation, and increased expression of proinflammatory factors, oxidative stress, and profibrotic growth factors. Treatment of these mice with the highly selective and potent FXR-activating ligand 6-alpha-ethyl-chenodeoxycholic acid (INT-747) ameliorates triglyceride accumulation by modulating fatty acid synthesis and oxidation, improves proteinuria, prevents podocyte loss, mesangial expansion, accumulation of extracellular matrix proteins, and increased expression of profibrotic growth factors and fibrosis markers, and modulates inflammation and oxidative stress. Our results therefore indicate that FXR activation could represent an effective therapy for treatment of abnormal renal lipid metabolism with associated inflammation, oxidative stress, and kidney pathology in patients affected by obesity. Diet-induced obesity is associated with proteinuria and glomerular disease in humans and rodents. We have shown that in mice fed a high-fat diet, increased renal expression of the transcriptional factor sterol-regulatory element binding protein-1 (SREBP-1) plays a critical role in renal lipid accumulation and increases the activity of proinflammatory cytokines and profibrotic growth factors. In the current study, we have determined a key role of the farnesoid X receptor (FXR) in modulating renal SREBP-1 activity, glomerular lesions, and proteinuria. We found that feeding a Western-style diet to DBA/2J mice results in proteinuria, podocyte loss, mesangial expansion, renal lipid accumulation, and increased expression of proinflammatory factors, oxidative stress, and profibrotic growth factors. Treatment of these mice with the highly selective and potent FXR-activating ligand 6-α-ethyl-chenodeoxycholic acid (INT-747) ameliorates triglyceride accumulation by modulating fatty acid synthesis and oxidation, improves proteinuria, prevents podocyte loss, mesangial expansion, accumulation of extracellular matrix proteins, and increased expression of profibrotic growth factors and fibrosis markers, and modulates inflammation and oxidative stress. Our results therefore indicate that FXR activation could represent an effective therapy for treatment of abnormal renal lipid metabolism with associated inflammation, oxidative stress, and kidney pathology in patients affected by obesity. Diet-induced obesity is associated with proteinuria and glomerular disease in humans and rodents. We have shown that in mice fed a high-fat diet, increased renal expression of the transcriptional factor sterol-regulatory element binding protein-1 (SREBP-1) plays a critical role in renal lipid accumulation and increases the activity of proinflammatory cytokines and profibrotic growth factors. In the current study, we have determined a key role of the farnesoid X receptor (FXR) in modulating renal SREBP-1 activity, glomerular lesions, and proteinuria. We found that feeding a Western-style diet to DBA/2J mice results in proteinuria, podocyte loss, mesangial expansion, renal lipid accumulation, and increased expression of proinflammatory factors, oxidative stress, and profibrotic growth factors. Treatment of these mice with the highly selective and potent FXR-activating ligand 6-α-ethyl-chenodeoxycholic acid (INT-747) ameliorates triglyceride accumulation by modulating fatty acid synthesis and oxidation, improves proteinuria, prevents podocyte loss, mesangial expansion, accumulation of extracellular matrix proteins, and increased expression of profibrotic growth factors and fibrosis markers, and modulates inflammation and oxidative stress. Our results therefore indicate that FXR activation could represent an effective therapy for treatment of abnormal renal lipid metabolism with associated inflammation, oxidative stress, and kidney pathology in patients affected by obesity. Diet-induced obesity is associated with proteinuria and glomerular disease in humans and rodents. We have shown that in mice fed a high-fat diet, increased renal expression of the transcriptional factor sterol-regulatory element binding protein-1 (SREBP-1) plays a critical role in renal lipid accumulation and increases the activity of proinflammatory cytokines and profibrotic growth factors. In the current study, we have determined a key role of the farnesoid X receptor (FXR) in modulating renal SREBP-1 activity, glomerular lesions, and proteinuria. We found that feeding a Western-style diet to DBA/2J mice results in proteinuria, podocyte loss, mesangial expansion, renal lipid accumulation, and increased expression of proinflammatory factors, oxidative stress, and profibrotic growth factors. Treatment of these mice with the highly selective and potent FXR-activating ligand 6-alpha-ethyl-chenodeoxycholic acid (INT-747) ameliorates triglyceride accumulation by modulating fatty acid synthesis and oxidation, improves proteinuria, prevents podocyte loss, mesangial expansion, accumulation of extracellular matrix proteins, and increased expression of profibrotic growth factors and fibrosis markers, and modulates inflammation and oxidative stress. Our results therefore indicate that FXR activation could represent an effective therapy for treatment of abnormal renal lipid metabolism with associated inflammation, oxidative stress, and kidney pathology in patients affected by obesity. |
Author | Wang, Xiaoxin X. Adorini, Luciano Pruzanski, Mark Gonzalez, Frank J. Lewis, Linda Shen, Yan Scherzer, Pnina Jiang, Tao Miyazaki-Anzai, Shinobu Levi, Moshe |
Author_xml | – sequence: 1 givenname: Xiaoxin X. surname: Wang fullname: Wang, Xiaoxin X. organization: Department of Medicine, University of Colorado Denver, and Veterans Affairs Medical Center, Aurora, Colorado – sequence: 2 givenname: Tao surname: Jiang fullname: Jiang, Tao organization: Department of Medicine, University of Colorado Denver, and Veterans Affairs Medical Center, Aurora, Colorado – sequence: 3 givenname: Yan surname: Shen fullname: Shen, Yan organization: Department of Medicine, University of Colorado Denver, and Veterans Affairs Medical Center, Aurora, Colorado – sequence: 4 givenname: Luciano surname: Adorini fullname: Adorini, Luciano organization: Intercept Pharmaceuticals, Perugia, Italy – sequence: 5 givenname: Mark surname: Pruzanski fullname: Pruzanski, Mark organization: Intercept Pharmaceuticals, New York, New York – sequence: 6 givenname: Frank J. surname: Gonzalez fullname: Gonzalez, Frank J. organization: Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; and – sequence: 7 givenname: Pnina surname: Scherzer fullname: Scherzer, Pnina organization: Nephrology and Hypertension Services, Hadassah University Hospital, Jerusalem, Israel – sequence: 8 givenname: Linda surname: Lewis fullname: Lewis, Linda organization: Department of Medicine, University of Colorado Denver, and Veterans Affairs Medical Center, Aurora, Colorado – sequence: 9 givenname: Shinobu surname: Miyazaki-Anzai fullname: Miyazaki-Anzai, Shinobu organization: Department of Medicine, University of Colorado Denver, and Veterans Affairs Medical Center, Aurora, Colorado – sequence: 10 givenname: Moshe surname: Levi fullname: Levi, Moshe organization: Department of Medicine, University of Colorado Denver, and Veterans Affairs Medical Center, Aurora, Colorado |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19776172$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kcFu1DAQhi1URNuFJ0BCERcuzTK2Ezu5IKEKKFIlLkXqzZrYDvXKsYOdIHh73O0WSg-cbGm-fzye75QchRgsIS8pbClt2VvczckG9FuABpotA-ifkJNSYTVthDgq957Tumvl9TE5zXkHAJQy-owc015KQSU7IT-vbmw1Ygo2R2eq6ypZbeclpmqKZvW42FztX6m8mwsw2QWH6F2eKgymMs4utQtm1dYcOBdGj9OEi4vhrBrdkGJ2-WyPzyku1oU1OXxOno7os31xODfk68cPV-cX9eWXT5_P31_WuunZUuuhGwapR66hk9CLTiBKtMAkZX079B0OIHirUXTGGGkN78aBGSG1BOhQ8A15d9d3XofJGm3DktCrObkJ0y8V0al_K8HdqG_xh2IdUN40pcGbQ4MUv682L2pyWVvvMdi4ZiU5F8DaAm_I60fkLq6p7CQrxoECtLwv0KuH8_wZ5F5JAfgdoMvicrLjXwTUrXh1L17txatb8SXVP0ppt-wdlE85_9_sb0bduQc |
CitedBy_id | crossref_primary_10_3389_fimmu_2020_00769 crossref_primary_10_1152_ajprenal_00209_2013 crossref_primary_10_3390_metabo11090608 crossref_primary_10_1111_jfbc_13476 crossref_primary_10_1016_j_dld_2010_03_015 crossref_primary_10_1074_jbc_M117_779520 crossref_primary_10_2337_db10_0019 crossref_primary_10_1038_s41598_019_52682_9 crossref_primary_10_1007_s11892_019_1263_x crossref_primary_10_1016_j_aohep_2019_06_022 crossref_primary_10_1111_1440_1681_13556 crossref_primary_10_1073_pnas_1323977111 crossref_primary_10_1152_ajprenal_00061_2024 crossref_primary_10_1016_j_jhep_2016_01_016 crossref_primary_10_1152_ajpgi_00177_2021 crossref_primary_10_2174_1381612829666221020162955 crossref_primary_10_1590_2175_8239_jbn_2023_0148en crossref_primary_10_3390_ijms21144939 crossref_primary_10_1016_j_cgh_2016_08_002 crossref_primary_10_1016_j_bbadis_2010_10_013 crossref_primary_10_18311_ti_2023_v30i4_30998 crossref_primary_10_1016_j_biochi_2015_08_001 crossref_primary_10_1371_journal_pone_0082275 crossref_primary_10_1159_000538038 crossref_primary_10_14814_phy2_13287 crossref_primary_10_1007_s10735_024_10308_z crossref_primary_10_1016_j_bbadis_2014_07_001 crossref_primary_10_1038_hr_2012_159 crossref_primary_10_1177_1535370219826526 crossref_primary_10_1038_nrd4592 crossref_primary_10_1038_s41401_021_00660_1 crossref_primary_10_1152_ajprenal_00088_2024 crossref_primary_10_1016_j_phymed_2023_154861 crossref_primary_10_1097_HC9_0000000000000343 crossref_primary_10_1186_s12986_015_0032_3 crossref_primary_10_3390_antiox13121540 crossref_primary_10_3389_fimmu_2023_1269261 crossref_primary_10_3760_cma_j_issn_0366_6999_20130774 crossref_primary_10_1152_ajprenal_00068_2011 crossref_primary_10_1152_ajprenal_00223_2015 crossref_primary_10_1042_BSR20212791 crossref_primary_10_1080_0886022X_2024_2359638 crossref_primary_10_1038_nrneph_2014_87 crossref_primary_10_1152_ajprenal_00005_2010 crossref_primary_10_1016_j_mam_2020_100935 crossref_primary_10_1096_fj_201900325R crossref_primary_10_1093_ckj_sfw094 crossref_primary_10_1161_HYPERTENSIONAHA_115_06417 crossref_primary_10_1038_s41598_017_10168_6 crossref_primary_10_1016_j_ajpath_2023_07_008 crossref_primary_10_1002_hep_27123 crossref_primary_10_1021_envhealth_3c00202 crossref_primary_10_1007_s12263_012_0295_5 crossref_primary_10_1152_ajprenal_00563_2018 crossref_primary_10_1152_ajprenal_00292_2023 crossref_primary_10_3748_wjg_v22_i41_9039 crossref_primary_10_1038_s12276_023_00932_2 crossref_primary_10_1111_dom_15199 crossref_primary_10_1038_nrneph_2011_104 crossref_primary_10_1016_j_cmet_2013_03_013 crossref_primary_10_1681_ASN_2017020222 crossref_primary_10_1016_j_kint_2022_01_029 crossref_primary_10_1016_j_ejphar_2018_09_009 crossref_primary_10_1038_nrneph_2010_56 crossref_primary_10_1074_jbc_M115_694323 crossref_primary_10_1053_j_gastro_2013_05_042 crossref_primary_10_1155_2020_3680397 crossref_primary_10_1515_mr_2024_0029 crossref_primary_10_2337_dc15_1182 crossref_primary_10_1021_acs_jmedchem_1c01017 crossref_primary_10_1093_ndt_gfx243 crossref_primary_10_1016_j_fct_2014_04_033 crossref_primary_10_1007_s00330_017_5298_6 crossref_primary_10_1177_1470320313507123 crossref_primary_10_3389_fphys_2023_1186477 crossref_primary_10_1016_j_jsbmb_2022_106065 crossref_primary_10_1111_j_1743_6109_2010_02073_x crossref_primary_10_1681_ASN_2014121271 crossref_primary_10_1016_j_aohep_2019_07_013 crossref_primary_10_1016_j_jbc_2022_102530 crossref_primary_10_1194_jlr_M033423 crossref_primary_10_1016_j_heliyon_2024_e41620 crossref_primary_10_1038_s41581_023_00741_w crossref_primary_10_1016_j_fbio_2024_104354 crossref_primary_10_2147_CIA_S295524 crossref_primary_10_1007_s11255_020_02731_4 crossref_primary_10_1016_j_biopha_2024_116533 crossref_primary_10_1111_eci_13748 crossref_primary_10_1007_s00592_020_01652_z crossref_primary_10_1038_srep37234 crossref_primary_10_1124_mol_110_064501 crossref_primary_10_1371_journal_pone_0085594 crossref_primary_10_1016_j_ekir_2024_08_002 crossref_primary_10_1016_j_semnephrol_2021_06_004 crossref_primary_10_1159_000341485 crossref_primary_10_1074_jbc_C117_794982 crossref_primary_10_1097_MNH_0b013e32835b4870 crossref_primary_10_1016_S2213_8587_14_70065_8 crossref_primary_10_2174_1389450124666221026152647 crossref_primary_10_1016_j_jsbmb_2017_01_010 crossref_primary_10_1080_14728222_2019_1559825 crossref_primary_10_2147_CIA_S431220 crossref_primary_10_1007_s00204_013_1078_5 crossref_primary_10_1038_s41581_021_00488_2 crossref_primary_10_3109_10799893_2014_885048 crossref_primary_10_1152_ajprenal_00047_2023 crossref_primary_10_1016_j_drudis_2012_05_012 crossref_primary_10_3390_jpm11080820 crossref_primary_10_3390_ijms24032408 crossref_primary_10_3389_fendo_2014_00186 crossref_primary_10_1089_met_2020_0141 crossref_primary_10_1038_s41392_022_01070_3 crossref_primary_10_3389_fphys_2020_00732 crossref_primary_10_1016_j_bbalip_2012_07_004 crossref_primary_10_3390_pharmaceutics15051360 crossref_primary_10_1016_j_jbc_2023_104975 crossref_primary_10_1016_j_bbadis_2011_04_003 crossref_primary_10_1002_jbt_22797 crossref_primary_10_1152_ajprenal_00338_2010 crossref_primary_10_1186_s12967_019_02170_5 crossref_primary_10_3389_fimmu_2018_02649 crossref_primary_10_1089_jir_2012_0008 crossref_primary_10_3748_wjg_v28_i39_5691 crossref_primary_10_1097_MNH_0b013e32833aa4ac crossref_primary_10_1016_j_molmed_2015_08_005 crossref_primary_10_1042_CS20200452 crossref_primary_10_1590_2175_8239_jbn_2023_0148pt crossref_primary_10_1002_path_5150 crossref_primary_10_1194_jlr_P040501 crossref_primary_10_1038_nrneph_2016_75 crossref_primary_10_1097_MNH_0000000000000374 crossref_primary_10_1097_MNH_0b013e3283374c09 crossref_primary_10_1038_s41581_020_00339_6 crossref_primary_10_1016_j_toxrep_2021_04_009 crossref_primary_10_3390_ijms222111416 crossref_primary_10_1042_CS20120190 |
Cites_doi | 10.2337/diabetes.53.4.890 10.1681/ASN.2006050420 10.1083/jcb.139.1.193 10.1016/S1097-2765(00)00051-4 10.1016/j.semnephrol.2007.02.009 10.1074/jbc.M110650200 10.1194/jlr.M500390-JLR200 10.1074/jbc.274.30.20874 10.4049/jimmunol.173.4.2280 10.1681/ASN.2007010089 10.2337/diabetes.54.8.2328 10.2337/diabetes.54.9.2628 10.1182/blood-2005-08-3465 10.1038/sj.ki.5002586 10.1093/ndt/17.7.1157 10.1074/jbc.M500801200 10.1053/S0270-9295(03)00132-3 10.1074/jbc.M004045200 10.1016/S0092-8674(00)00062-3 10.1152/ajprenal.00021.2007 10.1097/01.ASN.0000141966.69934.21 10.1111/j.1523-1755.2005.00733.x 10.2215/CJN.04071206 10.1210/en.2005-0641 10.1210/en.2004-0965 10.1097/01.ASN.0000141963.04540.3E 10.1161/01.RES.0000267856.00713.0a 10.2337/diabetes.51.3.825 10.1038/nature04330 10.2337/db06-1642 10.1681/ASN.2004080701 10.1172/JCI21025 10.1097/00041552-200405000-00006 10.1073/pnas.0506982103 10.1046/j.1523-1755.2001.0590041498.x 10.1161/ATVBAHA.107.152694 10.2337/db05-0603 10.1126/science.284.5418.1362 10.1021/jm025529g 10.1038/nrd2619 10.1038/ki.2008.128 10.1172/JCI25604 10.1101/gad.1138104 10.1053/j.gastro.2004.08.001 10.2337/db08-0061 10.1681/ASN.2007040471 10.1084/jem.20031132 10.1681/ASN.V1261211 10.1097/01.ASN.0000141965.28037.EE 10.1097/01.mnh.0000242172.06459.7c 10.1172/JCI24787 10.1073/pnas.88.15.6560 10.1124/jpet.108.145409 10.1038/sj.ki.5000406 10.1194/jlr.M800619-JLR200 |
ContentType | Journal Article |
Copyright | Copyright American Physiological Society Dec 2009 Copyright © 2009 American Physiological Society |
Copyright_xml | – notice: Copyright American Physiological Society Dec 2009 – notice: Copyright © 2009 American Physiological Society |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. 7X8 5PM |
DOI | 10.1152/ajprenal.00404.2009 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1522-1466 |
EndPage | F1596 |
ExternalDocumentID | PMC2801344 1913970031 19776172 10_1152_ajprenal_00404_2009 |
Genre | Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NIDDK NIH HHS grantid: U01 DK076134 – fundername: NIA NIH HHS grantid: R01 AG026529 |
GroupedDBID | --- 23M 2WC 39C 4.4 53G 5GY 5VS 6J9 8M5 AAFWJ AAYXX ACPRK ADBBV AENEX AFFNX ALMA_UNASSIGNED_HOLDINGS BAWUL BKKCC BTFSW C1A CITATION E3Z EBS EJD EMOBN F5P GX1 H13 ITBOX KQ8 OK1 P2P PQQKQ RAP RHI RPL RPRKH TR2 W8F WOQ XSW YSK CGR CUY CVF DIK ECM EIF NPM RHF K9. 7X8 5PM BKOMP |
ID | FETCH-LOGICAL-c492t-cb8bb7cf3c08709686aa7ae0271295b98ab0635ca68ddd7ed38fb2d67c7008a63 |
ISSN | 1931-857X 1522-1466 0363-6127 |
IngestDate | Thu Aug 21 14:13:51 EDT 2025 Fri Jul 11 09:25:26 EDT 2025 Mon Jun 30 08:11:04 EDT 2025 Wed Feb 19 01:56:32 EST 2025 Thu Apr 24 23:02:07 EDT 2025 Tue Jul 01 03:46:16 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c492t-cb8bb7cf3c08709686aa7ae0271295b98ab0635ca68ddd7ed38fb2d67c7008a63 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 X. X. Wang and T. Jiang contributed equally to this work. |
PMID | 19776172 |
PQID | 230100539 |
PQPubID | 48265 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2801344 proquest_miscellaneous_733602501 proquest_journals_230100539 pubmed_primary_19776172 crossref_primary_10_1152_ajprenal_00404_2009 crossref_citationtrail_10_1152_ajprenal_00404_2009 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2009-12-01 |
PublicationDateYYYYMMDD | 2009-12-01 |
PublicationDate_xml | – month: 12 year: 2009 text: 2009-12-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Bethesda – name: Bethesda, MD |
PublicationTitle | American Journal of Physiology - Renal Physiology |
PublicationTitleAlternate | Am J Physiol Renal Physiol |
PublicationYear | 2009 |
Publisher | American Physiological Society |
Publisher_xml | – name: American Physiological Society |
References | B20 B21 B22 B23 B24 B25 Henegar JR (B17) 2001; 12 B26 B27 B28 B29 B30 B31 B32 B33 B34 B35 B36 B37 B38 B39 B1 B2 B3 B4 B5 B6 B7 B8 B9 B40 B41 B42 B43 B44 B45 B46 B47 B48 B49 B50 B51 B52 B53 B10 B54 B11 B55 B12 B13 B14 B15 B16 B18 B19 16914959 - Curr Opin Nephrol Hypertens. 2006 Sep;15(5):481-6 15944339 - J Am Soc Nephrol. 2005 Aug;16(8):2385-94 15136591 - J Exp Med. 2004 May 17;199(10):1305-15 16410358 - Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1006-11 15504931 - J Am Soc Nephrol. 2004 Nov;15(11):2775-91 15521018 - Gastroenterology. 2004 Nov;127(5):1497-512 16210374 - Endocrinology. 2006 Jan;147(1):44-50 16936198 - Diabetes. 2006 Sep;55(9):2502-9 11872687 - Diabetes. 2002 Mar;51(3):825-32 19174369 - J Lipid Res. 2009 Jun;50(6):1090-100 17699463 - Clin J Am Soc Nephrol. 2007 May;2(3):550-62 10980195 - J Biol Chem. 2000 Nov 24;275(47):36703-7 16046298 - Diabetes. 2005 Aug;54(8):2328-35 11030617 - Cell. 2000 Sep 15;102(6):731-44 15047603 - Diabetes. 2004 Apr;53(4):890-8 17533008 - Semin Nephrol. 2007 May;27(3):309-20 15564327 - Endocrinology. 2005 Mar;146(3):984-91 16688121 - Kidney Int. 2006 Jun;69(11):1969-76 17585076 - Circ Res. 2007 Jun 22;100(12):1686-95 15504932 - J Am Soc Nephrol. 2004 Nov;15(11):2792-800 10334992 - Science. 1999 May 21;284(5418):1362-5 16046411 - J Biol Chem. 2005 Sep 16;280(37):32317-25 15073488 - Curr Opin Nephrol Hypertens. 2004 May;13(3):299-305 9314539 - J Cell Biol. 1997 Oct 6;139(1):193-204 17660268 - Diabetes. 2007 Oct;56(10):2485-93 17596532 - Am J Physiol Renal Physiol. 2007 Sep;293(3):F670-9 16557297 - J Clin Invest. 2006 Apr;116(4):1102-9 16400329 - Nature. 2006 Jan 26;439(7075):484-9 16123351 - Diabetes. 2005 Sep;54(9):2628-37 18418356 - Kidney Int. 2008 Jul;74(1):22-36 18029909 - Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2606-11 14729567 - Genes Dev. 2004 Jan 15;18(2):157-69 15294940 - J Immunol. 2004 Aug 15;173(4):2280-7 1713682 - Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6560-4 16455954 - Blood. 2006 Jun 1;107(11):4354-63 15146238 - J Clin Invest. 2004 May;113(10):1408-18 18670431 - Nat Rev Drug Discov. 2008 Aug;7(8):678-93 16316337 - Kidney Int. 2005 Dec;68(6):2608-20 15504929 - J Am Soc Nephrol. 2004 Nov;15(11):2768-72 18511444 - Diabetes. 2008 Jun;57(6):1439-45 16341264 - J Clin Invest. 2006 Jan;116(1):49-58 10409630 - J Biol Chem. 1999 Jul 23;274(30):20874-8 14631561 - Semin Nephrol. 2003 Nov;23(6):532-43 11373344 - J Am Soc Nephrol. 2001 Jun;12(6):1211-7 18981289 - J Pharmacol Exp Ther. 2009 Feb;328(2):469-77 11030332 - Mol Cell. 2000 Sep;6(3):517-26 11260414 - Kidney Int. 2001 Apr;59(4):1498-509 17035610 - J Am Soc Nephrol. 2006 Nov;17(11):2992-8 17855643 - J Am Soc Nephrol. 2007 Oct;18(10):2715-23 17928825 - Kidney Int. 2008 Jan;73(1):19-33 12166927 - J Med Chem. 2002 Aug 15;45(17):3569-72 18178797 - J Am Soc Nephrol. 2008 Jan;19(1):24-33 11875060 - J Biol Chem. 2002 May 24;277(21):18919-27 12105233 - Nephrol Dial Transplant. 2002 Jul;17(7):1157-9 16186601 - J Lipid Res. 2005 Dec;46(12):2595-604 |
References_xml | – ident: B11 doi: 10.2337/diabetes.53.4.890 – ident: B43 doi: 10.1681/ASN.2006050420 – ident: B31 doi: 10.1083/jcb.139.1.193 – ident: B14 doi: 10.1016/S1097-2765(00)00051-4 – ident: B5 doi: 10.1016/j.semnephrol.2007.02.009 – ident: B44 doi: 10.1074/jbc.M110650200 – ident: B15 doi: 10.1194/jlr.M500390-JLR200 – ident: B1 doi: 10.1074/jbc.274.30.20874 – ident: B13 doi: 10.4049/jimmunol.173.4.2280 – ident: B25 doi: 10.1681/ASN.2007010089 – ident: B49 doi: 10.2337/diabetes.54.8.2328 – ident: B37 doi: 10.2337/diabetes.54.9.2628 – ident: B7 doi: 10.1182/blood-2005-08-3465 – ident: B48 doi: 10.1038/sj.ki.5002586 – ident: B34 doi: 10.1093/ndt/17.7.1157 – ident: B23 doi: 10.1074/jbc.M500801200 – ident: B6 doi: 10.1053/S0270-9295(03)00132-3 – ident: B8 doi: 10.1074/jbc.M004045200 – ident: B41 doi: 10.1016/S0092-8674(00)00062-3 – ident: B9 doi: 10.1152/ajprenal.00021.2007 – ident: B52 doi: 10.1097/01.ASN.0000141966.69934.21 – ident: B20 doi: 10.1111/j.1523-1755.2005.00733.x – ident: B47 doi: 10.2215/CJN.04071206 – ident: B53 doi: 10.1210/en.2005-0641 – ident: B42 doi: 10.1210/en.2004-0965 – ident: B2 doi: 10.1097/01.ASN.0000141963.04540.3E – ident: B3 doi: 10.1161/01.RES.0000267856.00713.0a – ident: B39 doi: 10.2337/diabetes.51.3.825 – ident: B50 doi: 10.1038/nature04330 – ident: B22 doi: 10.2337/db06-1642 – ident: B21 doi: 10.1681/ASN.2004080701 – ident: B51 doi: 10.1172/JCI21025 – ident: B27 doi: 10.1097/00041552-200405000-00006 – ident: B55 doi: 10.1073/pnas.0506982103 – ident: B24 doi: 10.1046/j.1523-1755.2001.0590041498.x – ident: B26 doi: 10.1161/ATVBAHA.107.152694 – ident: B36 doi: 10.2337/db05-0603 – ident: B29 doi: 10.1126/science.284.5418.1362 – ident: B33 doi: 10.1021/jm025529g – ident: B45 doi: 10.1038/nrd2619 – ident: B19 doi: 10.1038/ki.2008.128 – ident: B28 doi: 10.1172/JCI25604 – ident: B54 doi: 10.1101/gad.1138104 – ident: B12 doi: 10.1053/j.gastro.2004.08.001 – ident: B38 doi: 10.2337/db08-0061 – ident: B46 doi: 10.1681/ASN.2007040471 – ident: B40 doi: 10.1084/jem.20031132 – volume: 12 start-page: 1211 year: 2001 ident: B17 publication-title: J Am Soc Nephrol doi: 10.1681/ASN.V1261211 – ident: B4 doi: 10.1097/01.ASN.0000141965.28037.EE – ident: B35 doi: 10.1097/01.mnh.0000242172.06459.7c – ident: B32 doi: 10.1172/JCI24787 – ident: B18 doi: 10.1073/pnas.88.15.6560 – ident: B30 doi: 10.1124/jpet.108.145409 – ident: B10 doi: 10.1038/sj.ki.5000406 – ident: B16 doi: 10.1194/jlr.M800619-JLR200 – reference: 12166927 - J Med Chem. 2002 Aug 15;45(17):3569-72 – reference: 15944339 - J Am Soc Nephrol. 2005 Aug;16(8):2385-94 – reference: 16046298 - Diabetes. 2005 Aug;54(8):2328-35 – reference: 15521018 - Gastroenterology. 2004 Nov;127(5):1497-512 – reference: 15504929 - J Am Soc Nephrol. 2004 Nov;15(11):2768-72 – reference: 15047603 - Diabetes. 2004 Apr;53(4):890-8 – reference: 17533008 - Semin Nephrol. 2007 May;27(3):309-20 – reference: 11875060 - J Biol Chem. 2002 May 24;277(21):18919-27 – reference: 15073488 - Curr Opin Nephrol Hypertens. 2004 May;13(3):299-305 – reference: 11030332 - Mol Cell. 2000 Sep;6(3):517-26 – reference: 16688121 - Kidney Int. 2006 Jun;69(11):1969-76 – reference: 10409630 - J Biol Chem. 1999 Jul 23;274(30):20874-8 – reference: 16186601 - J Lipid Res. 2005 Dec;46(12):2595-604 – reference: 15504931 - J Am Soc Nephrol. 2004 Nov;15(11):2775-91 – reference: 17699463 - Clin J Am Soc Nephrol. 2007 May;2(3):550-62 – reference: 14729567 - Genes Dev. 2004 Jan 15;18(2):157-69 – reference: 16046411 - J Biol Chem. 2005 Sep 16;280(37):32317-25 – reference: 11030617 - Cell. 2000 Sep 15;102(6):731-44 – reference: 18418356 - Kidney Int. 2008 Jul;74(1):22-36 – reference: 15564327 - Endocrinology. 2005 Mar;146(3):984-91 – reference: 16210374 - Endocrinology. 2006 Jan;147(1):44-50 – reference: 11872687 - Diabetes. 2002 Mar;51(3):825-32 – reference: 15146238 - J Clin Invest. 2004 May;113(10):1408-18 – reference: 11373344 - J Am Soc Nephrol. 2001 Jun;12(6):1211-7 – reference: 12105233 - Nephrol Dial Transplant. 2002 Jul;17(7):1157-9 – reference: 10980195 - J Biol Chem. 2000 Nov 24;275(47):36703-7 – reference: 18029909 - Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2606-11 – reference: 16936198 - Diabetes. 2006 Sep;55(9):2502-9 – reference: 16123351 - Diabetes. 2005 Sep;54(9):2628-37 – reference: 16410358 - Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1006-11 – reference: 18670431 - Nat Rev Drug Discov. 2008 Aug;7(8):678-93 – reference: 17660268 - Diabetes. 2007 Oct;56(10):2485-93 – reference: 17596532 - Am J Physiol Renal Physiol. 2007 Sep;293(3):F670-9 – reference: 18981289 - J Pharmacol Exp Ther. 2009 Feb;328(2):469-77 – reference: 15294940 - J Immunol. 2004 Aug 15;173(4):2280-7 – reference: 16914959 - Curr Opin Nephrol Hypertens. 2006 Sep;15(5):481-6 – reference: 18511444 - Diabetes. 2008 Jun;57(6):1439-45 – reference: 18178797 - J Am Soc Nephrol. 2008 Jan;19(1):24-33 – reference: 10334992 - Science. 1999 May 21;284(5418):1362-5 – reference: 16316337 - Kidney Int. 2005 Dec;68(6):2608-20 – reference: 9314539 - J Cell Biol. 1997 Oct 6;139(1):193-204 – reference: 1713682 - Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6560-4 – reference: 16455954 - Blood. 2006 Jun 1;107(11):4354-63 – reference: 17855643 - J Am Soc Nephrol. 2007 Oct;18(10):2715-23 – reference: 14631561 - Semin Nephrol. 2003 Nov;23(6):532-43 – reference: 16557297 - J Clin Invest. 2006 Apr;116(4):1102-9 – reference: 17585076 - Circ Res. 2007 Jun 22;100(12):1686-95 – reference: 17928825 - Kidney Int. 2008 Jan;73(1):19-33 – reference: 11260414 - Kidney Int. 2001 Apr;59(4):1498-509 – reference: 16400329 - Nature. 2006 Jan 26;439(7075):484-9 – reference: 19174369 - J Lipid Res. 2009 Jun;50(6):1090-100 – reference: 15504932 - J Am Soc Nephrol. 2004 Nov;15(11):2792-800 – reference: 16341264 - J Clin Invest. 2006 Jan;116(1):49-58 – reference: 15136591 - J Exp Med. 2004 May 17;199(10):1305-15 – reference: 17035610 - J Am Soc Nephrol. 2006 Nov;17(11):2992-8 |
SSID | ssj0001121 ssj0022686 |
Score | 2.3711061 |
Snippet | Diet-induced obesity is associated with proteinuria and glomerular disease in humans and rodents. We have shown that in mice fed a high-fat diet, increased... Diet-induced obesity is associated with proteinuria and glomerular disease in humans and rodents. We have shown that in mice fed a high-fat diet, increased... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | F1587 |
SubjectTerms | Animals Chenodeoxycholic Acid - analogs & derivatives Chenodeoxycholic Acid - pharmacology Diet Diet - adverse effects Extracellular Matrix Proteins - antagonists & inhibitors Fatty Acids - antagonists & inhibitors Fibrosis - etiology Glomerular Mesangium - pathology Inflammation Mediators - metabolism Intercellular Signaling Peptides and Proteins - metabolism Kidney - metabolism Kidney - pathology Kidney diseases Kidney Glomerulus - pathology Kidneys Lipid Metabolism Lipids Male Medical disorders Metabolism Mice Mice, Inbred DBA Mice, Knockout Nephritis - etiology Nephritis - pathology Oxidative Stress - drug effects Podocytes - pathology Proteinuria - etiology Proteinuria - physiopathology Receptors, Cytoplasmic and Nuclear - drug effects Receptors, Cytoplasmic and Nuclear - metabolism Sterol Regulatory Element Binding Protein 1 - metabolism Triglycerides - antagonists & inhibitors |
Title | The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria |
URI | https://www.ncbi.nlm.nih.gov/pubmed/19776172 https://www.proquest.com/docview/230100539 https://www.proquest.com/docview/733602501 https://pubmed.ncbi.nlm.nih.gov/PMC2801344 |
Volume | 297 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKkBAvCDY-ygD5AfHSpizO92OFmCbQEEidFJ4iO3FEUJtUayIN_hX-We5sx0nZQMBLVNnXJMrvl_Pd5XxHyMsgKLgAO8MRbqmKajOHe3nksEJ6YZFErOS4Ufj8Q3h24b9Lg3Qy-THKWupasci_37iv5H9QhTHAFXfJ_gOy9qQwAL8BXzgCwnD8a4xLfgnaqqmKWToD7SW34ERjfxtsyyXxmwCam-tqCwIb2QLk674tRlHJ1gGXvMMUAC0HNwUM0bsZ8eGX4Ew3O12GQFcUaLA7Zqdzk61Vaz_7jOpQqJCJitkvAEMcHEaGKL7WNGnFm6uqnqU2n6cyMyve2BiQ2UfyeeDzssD0Qb2_u8PwTLMXxEhGCSHSKF5wikFrh2PNzHTqrqHgWM-euoFep6-vAAFWlOVft-q5LVBJqdBZMpYGGLcbRQoX7F804obl0CYp9lO3yG0GPgi2x3j_aShFD4aqa8pYwTVf33BFVZBWn2Pf6rnmyvyakTsycVb3yT3jm9ClJtoDMpH1ITla1rxtNt_oK_rRAnhI7pybpIwjcgU0pJaGNKU9DamlIVU3TRUN6UBDCpyiYxoauTEN57Qn4VyJjyj4kFycvl29OXNMQw8n9xPWOrmIhYjy0stPYJlIwjjkPOLyhEVgdQYiibkAiznIeRgXRRHJwotLwYowyiMwVXnoPSIHdVPLJ4TGuWS-F5aSlcwXYcy5zwsvOBExVl_y5ZSw_oFnual2j01X1pnyegOW9YBlCjBsx5pMydz-aauLvfxZ_LhHMjPv1y4Dl97FlQ1mqZ0FlY3f4Xgtm26XYQVSdD3cKXmsYR-uZvgyJdEeIawAVoPfn6mrL6oqPANb0_P9p7895zG5O7x6z8hBe9nJ52BRt-KFYvZPTivTjQ |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+farnesoid+X+receptor+modulates+renal+lipid+metabolism+and+diet-induced+renal+inflammation%2C+fibrosis%2C+and+proteinuria&rft.jtitle=American+journal+of+physiology.+Renal+physiology&rft.au=Wang%2C+Xiaoxin+X&rft.au=Jiang%2C+Tao&rft.au=Shen%2C+Yan&rft.au=Adorini%2C+Luciano&rft.date=2009-12-01&rft.eissn=1522-1466&rft.volume=297&rft.issue=6&rft.spage=F1587&rft_id=info:doi/10.1152%2Fajprenal.00404.2009&rft_id=info%3Apmid%2F19776172&rft.externalDocID=19776172 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1931-857X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1931-857X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1931-857X&client=summon |